At the largest hospital in Brooklyn, doctors are working to address disparities for patients facing advanced heart failure.

Nat Clin Pract Cardiovasc Med. 2006;3(7):346-347. Since the first widespread clinical application of left ventricular assist devices (LVADs) for patients with end-stage heart failure in the ...

AngioDynamics announced today that it launched a new trial evaluating its AlphaVac F18 system in treating pulmonary embolism ...

The company’s RECOVER-AV trial is intended to further the adoption of its AlphaVac F1885 system in the European market.

Multi-channel models enhance cardiotoxicity testing, offering more accurate and human-relevant insights for safer drug ...

Boston Scientific (NYSE: BSX) received FDA approval to expand the indication for its current-generation Ingevity+ pacing ...

A Vascular Access Device (VAD) is a medical device designed to provide access to a patient’s bloodstream for various medical treatments, procedures, and interventions. It allows healthcare ...

AngioDynamics, Inc. announced the launch of the RECOVER AV trial of the company’s AlphaVac F18⁸⁵ multipurpose mecha ...

CVKD READ THE FULL CVKD RESEARCH REPORT We are initiating coverage of Cadrenal Therapeutics, Inc. (NASDAQ:CVKD) with a $30.00 valuation. Cadrenal is a biopharmaceutical developing innovative therapies ...

This year, the SOFMEDICA Group celebrates three decades of innovation in the healthcare industry. Founded in 1994, the Group ...

NIDCM is characterized by left-ventricular or biventricular dilatation and contractile ... people with NIDCM each year based largely on LVEF criteria. However, most device recipients don't end up with ...

AngioDynamics, Inc. (NASDAQ: ANGO), a leading and transformative medical technology company focused on restoring healthy blood flow in the body’s vasc ...